First Patient Enrolled in Biogen’s Phase 3b Study to Evaluate Extended Interval Dosing (EID) with Natalizumab in Multiple Sclerosis
Study will provide the first randomized, controlled efficacy and safety data of every-six-week dosing for natalizumab
CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- The first patient has been enrolled in a global Phase 3b study evaluating the efficacy and safety of extended interval dosing (EID; every six weeks) for natalizumab compared to standard interval dosing (SID) in patients with relapsing multiple sclerosis (MS), Biogen Inc. (Nasdaq: BIIB) announced. Currently commercialized under the brand name TYSABRI®, natalizumab 300 mg dosed every four weeks is the only approved dosing regimen.
The new study, NOVA (NCT03689972), is a two-year, prospective, randomized, interventional, controlled, open-label, rater-blinded, international Phase 3b study that will assess the efficacy, safety and tolerability of six-week natalizumab dosing intervals in people with relapsing-remitting MS. Patients who switch to EID after one year of treatment with natalizumab SID will be evaluated in relation to patients receiving continued SID treatment. The study will enroll approximately 480 patients worldwide. The primary endpoint is the number of new or newly enlarging T2 hyperintense lesions at week 48.
“For more than a decade, natalizumab has been considered a highly effective treatment option for patients with relapsing forms of MS,” said Alfred Sandrock, Jr., M.D., Ph.D., executive vice president and chief medical officer at Biogen. “The NOVA study may generate valuable data that we hope will answer questions for the scientific community about the efficacy of natalizumab when its dosing schedule is extended to every six weeks, and in conjunction with prior safety analyses, may inform on the drug’s benefit-risk profile.”
NOVA was initiated following analyses that showed that EID was associated with a significant reduction in the risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection. The pre-specified, retrospective analysis of the U.S. TOUCH (TYSABRI® Outreach: United Commitment to Health) REMS program examined the impact of EID as compared to SID on the risk of PML, and the NOVA study aims to assess the efficacy of EID natalizumab to further evaluate the drug’s benefit-risk profile.
TYSABRI is a disease modifying therapy (DMT) approved in more than 80 countries, including the U.S., the European Union, Canada, Australia and Switzerland. In the U.S., TYSABRI is indicated as monotherapy for the treatment of patients with relapsing forms of MS. In the European Union, it is indicated as a single DMT in adults with highly active relapsing-remitting MS (RRMS) for patients with highly active disease activity despite a full and adequate course of treatment with at least one DMT or patients with rapidly evolving severe RRMS. TYSABRI has been used to treat RRMS for more than 10 years, with nearly 191,000 people treated worldwide and over 650,000 patient-years of experience.1
TYSABRI increases the risk of PML, a rare opportunistic viral infection of the brain which has been associated with death or severe disability. Risk factors that increase the risk of PML are the presence of anti-JCV antibodies, prior immunosuppressant use and longer TYSABRI treatment duration. Patients who have all three risk factors have the highest risk of developing PML.
TYSABRI also increases the risk of developing encephalitis and meningitis caused by herpes simplex and varicella zoster viruses, and serious, life-threatening and sometimes fatal cases have been reported in the post-marketing setting in MS patients receiving TYSABRI. Other serious adverse events that have occurred in TYSABRI-treated patients include hypersensitivity reactions (e.g., anaphylaxis) and infections, including opportunistic and other atypical infections. Clinically significant liver injury, including acute liver failure requiring transplant, has also been reported in the post-marketing setting.
Please see full Prescribing Information, including Boxed Warning, and Medication Guide as well as Important Safety Information for TYSABRI in the U.S., or visit your respective country’s product website.
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy and is focused on advancing neuroscience research programs in Alzheimer’s disease and dementia, multiple sclerosis and neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry and acute neurology. Biogen also manufactures and commercializes biosimilars of advanced biologics.
We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media – Twitter, LinkedIn, Facebook, YouTube.
Biogen Safe Harbor
This news release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, relating to the potential benefits, safety and efficacy of EID natalizumab; the treatment of multiple sclerosis; the clinical development program for EID natalizumab; the enrollment of the NOVA study of EID natalizumab; risks and uncertainties associated with drug development and commercialization; and the potential of Biogen’s commercial business, including natalizumab. These forward-looking statements may be accompanied by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “possible,” “will” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented.
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation, risks that Biogen may not fully enroll the NOVA study or it will take longer than expected; uncertainty of success in the development and potential commercialization of EID natalizumab; unexpected concerns that may arise from additional data, analysis or results obtained during the NOVA study; regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of EID natalizumab; the occurrence of adverse safety events; risks of unexpected costs or delays; the risks of other unexpected hurdles; failure to protect and enforce Biogen’s data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; and product liability claims. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Biogen’s expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in Biogen’s most recent annual or quarterly report and in other reports Biogen has filed with the Securities and Exchange Commission. These statements are based on Biogen’s current beliefs and expectations and speak only as of the date of this news release. Biogen does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
+1 617 679 4945
+1 781 464 2442
1 Global Natalizumab (TYSABRI) Postmarketing PML Update, August 2018.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 21, 201916.7.2019 22:00:00 CEST | Press release
LYON, France and CAMBRIDGE, Mass., July 16, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP) announced that its 2019 Annual General Meeting was held in Paris on Friday, June 21, 2019. At the meeting, all resolutions for which management recommended a vote in favor, were adopted, including: Appointment of Jean-Paul KRESS as director; he was subsequently appointed to the position of Chairman of the Board of Directors; Renewal of the term of office of each of the following as a member of the Board of Directors: o Gil BEYEN; o Luc DOCHEZ; o Philippe ARCHINARD; o Galenos, represented by Sven ANDREASSON; Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2018 and quietus of directors; Allocation of the financial year's results; Approval of regulatory agreements and commitments referred to in Article L.225-38 of the French Commercial Code; Approval of the regulations of the share subscription and/or purchase
LGC Capital Ltd. Announces Change in Financial Year-End16.7.2019 18:30:00 CEST | Press release
MONTRÉAL, July 16, 2019 (GLOBE NEWSWIRE) -- LGC Capital Ltd. (TSX-V: LG / OTCQB: LGGCF) wishes to announce that it is changing its financial year-end to December 31 from its current year-end of September 30. As a result, LGC will file an additional interim report as at September 30, 2019 and will report audited financial results for a 15-month transition year from October 1, 2018 to December 31, 2019 (with a comparative of the 12 months ended September 30, 2018). Afterwards, LGC will revert to a customary reporting calendar based on a December 31 year-end, with fiscal quarters ending on the last day of March, June, September and December each year. LGC believes this change of financial year-end will allow it to complete the audit requirements of its investee companies with greater efficiency and will be useful to consolidate other companies in the future. The notice for the change in financial year-end required under Regulation 51-102 respecting Continuous Disclosure Obligations will b
UPDATE -- OneMarket Introduces First Customer Activation Platform Dedicated to Retail16.7.2019 16:53:00 CEST | Press release
First-of-its-kind Platform Pairs Data Management and Customer Engagement to Transform How Retailers Monetize Customer Relationships SAN FRANCISCO, July 16, 2019 (GLOBE NEWSWIRE) -- OneMarket (ASX: OMN), today announced the availability of the OneMarket Customer Activation Platform, the first combined data management platform and solutions ecosystem built exclusively to help retailers, brands and venues identify, understand and communicate with customers to build longer-lasting, more profitable relationships. Combining decades of retail and customer lifecycle expertise, OneMarket traces its heritage to the Westfield Corporation and Westfield Labs. As a newly independent entity, OneMarket is leveraging the technological assets and financial investments made under Westfield to bring a turn-key, cloud-based platform technology to market for the benefit of the retail industry. The OneMarket Customer Activation Platform is the company’s first major technology release, purpose-built to addres
OneMarket Introduces First Customer Activation Platform Dedicated to Retail16.7.2019 16:00:00 CEST | Press release
First-of-its-kind Platform Pairs Data Management and Customer Engagement to Transform How Retailers SAN FRANCISCO, July 16, 2019 (GLOBE NEWSWIRE) -- OneMarket (ASX: OMN), today announced the availability of the OneMarket Customer Activation Platform, the first combined data management platform and solutions ecosystem built exclusively to help retailers, brands and venues identify, understand and communicate with customers to build longer-lasting, more profitable relationships. Combining decades of retail and customer lifecycle expertise, OneMarket traces its heritage to the Westfield Corporation and Westfield Labs. As a newly independent entity, OneMarket is leveraging the technological assets and financial investments made under Westfield to bring a turn-key, cloud-based platform technology to market for the benefit of the retail industry. The OneMarket Customer Activation Platform is the company’s first major technology release, purpose-built to address the complex customer identific
Agreement with Eurekahedge Expands eVestment’s Hedge Fund Data Offering16.7.2019 14:00:00 CEST | Press release
ATLANTA, July 16, 2019 (GLOBE NEWSWIRE) -- eVestment, a global leader in institutional investment data and analytics, today announced an agreement with Eurekahedge to offer Eurekahedge fund data and indices to clients of eVestment’s suite of Analytics solutions. eVestment Analytics clients will now have access to Eurekahedge’s global hedge fund data and indices, which cover over 30,000 hedge funds and funds of hedge funds spanning North American, European, Asian, Latin American and emerging markets. This expansion of data capabilities on the eVestment platform furthers eVestment’s focus on providing the most comprehensive institutional investment data to clients around the world across a wide variety of asset classes, including traditional investment strategies, hedge funds, funds of hedge funds and private markets investment opportunities. “Our clients need the most comprehensive data available to make the best decisions,” said eVestment Global Head of Insights John Molesphini. “Addin
ClarionDoor Adds New Head of Data and Analytics16.7.2019 11:00:00 CEST | Press release
Increasing efficiency of data-intensive processes creates deeper need for data scientists by insurers. SANTA BARBARA, Calif., July 16, 2019 (GLOBE NEWSWIRE) -- The explosion of Big Data in the last five to ten years has hit the insurance industry hard due to the inability of legacy technology systems to effectively capture, store, integrate, and utilize unstructured data, in particular, and created an urgent need for data scientists. Forward-thinking insurance industry solution providers, like ClarionDoor, Inc. (ClarionDoor) , developer of enterprise-class, cloud-based rating, quoting, and issuance solutions for property and casualty (P&C) insurers, are adding bench strength with significant data mastery capabilities to help offset the gap for insurance company clients. Notably, ClarionDoor recently added Mark Heslop to the leadership team as the company’s new Head of Data and Analytics. “Mark is an important addition to our team,” said Michael DeGusta, CEO of ClarionDoor. “He will be